Uptake Medical said yesterday that its InterVapor device for treating emphysema is back on the market in Europe after its acquisition for an undisclosed amount by an affiliate of Broncus Medical. Broncus set its purchase up under a new entity based in Seattle, Uptake Medical Technology, and plans to add markets in Australia and Asia to […]
Uptake Medical said today that data from a study recently published in the journal Lancet indicated that patients who underwent therapy using the company’s InterVapor system experienced statistically significant benefits in both lung function and quality of life. The InterVapor uses heated water vapor to reduce bronchoscopic lung volume in patients with heterogenous upper lobe emphysema, […]
Uptake Medical said today it launched a registry trial of its InterVapor system to investigate long-term clinical results in severe emphysema patients. The InterVapor uses heated water vapor to reduce bronchoscopic lung volume in patients with heterogenous upper lobe emphysema, the company said. “Until InterVapor, severe emphysema was typically treated either by requiring patients to […]
Uptake Medical said it’s InterVapor targeted vapor therapy system has been used in the 1st-ever regional lung cancer tumor ablation procedure. The InterVapor uses heated water vapor to reduce bronchoscopic lung volume in patients with heterogenous upper lobe emphysema, the company said. The patient treated with the system was diagnosed with colorectal cancer that metastasized […]
Uptake Medical said today that data from a clinical study of its InterVapor device showed significant improvements in lung function and quality of life in patients treated with the device. The InterVapor uses heated water vapor to reduce bronchoscopic lung volume in patients with heterogenous upper lobe emphysema, the Tustin, Calif.-based company said. “Uptake Medical is […]
Uptake Medical said today it won CE Mark approval in the European Union for its InterVapor ablation device, now indicated to treat patients who suffer from severe emphysema. The InterVapor device uses heated water vapor to reduce bronchoscopic lung volume in patients with heterogenous upper lobe emphysema, the Tustin, Calif.-based company said. “The traditional treatment […]
Carticept Medical closed a $10 million financing led by existing investors Domain Associates, New Enterprise Associates and SonoSite Inc.
The Alpharetta, Ga.-based company said it will use the proceeds to fund the commercial launch of its Navigator computer-controlled drug delivery system. The device uses ultrasound guidance to deliver medications for joint pain.
Merck Global Health Innovation Fund will invest up to $17 million in medical app maker Physicians Interactive Holdings. The financing includes $8.5 million up front, but could double if the mHealth marketer meets Merck’s milestones.
The Marlborough, Mass.-based company plans to use the Merck funds to grow "4 key products," including its flagship medical resources app Skyscape.
Updated Dec. 23, 2011, to correct that the HeartNavigator is inserted through a small incision in the leg, not in the chest.
Philips Healthcare (NYSE:PHG) landed FDA clearance for its HeartNavigator heart valve replacement system.
Medical City Dallas Hospital became the first U.S. hospital to use the system, which was launched in Europe in the first quarter of this year.
Calgary Scientific’s ResolutionMD mobile got a green light from the FDA for viewing diagnostic images on iPhones and iPads.
The ResolutionMD mobile app was built from existing ResolutionMD software, which recieved FDA clearance in 2006. The app already has the greenlight from Canada’s regulatory body, Health Canada and has a CE Mark for distribution in Europe.
Uptake Medical Receives CE Mark for InterVapor – Endoscopic Lung Volume Reduction for Treatment of Severe Emphysema – and Announces Positive Clinical Results
New treatment provides clinically meaningful improvements in lung function and quality of life
AMSTERDAM and TUSTIN, Calif., Sept. 26, 2011 /PRNewswire/ — Uptake Medical® today announced it has received the CE Mark (Conformite Europeenne) for the InterVapor™ System – the first endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body’s natural healing processes without leaving foreign materials behind. The CE Mark will allow Uptake Medical to commercialize InterVapor in key markets within the European Community.